← All Apellis Pharmaceuticals, INC filings

Apellis Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
APLS
Apellis Pharmaceuticals, INC
10-K/A: Apellis Pharmaceuticals Files 10-K/A Amendment
Apellis Pharmaceuticals, Inc. has filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, to include Part III information previously omitted.
NASDAQ
APLS
Apellis Pharmaceuticals, INC
10-K: Apellis Pharmaceuticals Reports First Annual Profit, Advances Pipeline
Apellis Pharmaceuticals achieved its first net income of $22.4 million in 2025, driven by strong licensing revenue and continued commercialization of SYFOVRE and EMPAVELI, despite a decline in SYFOVRE sales.
NASDAQ
APLS
Apellis Pharmaceuticals, INC
10-K: Apellis Pharmaceuticals Reports Promising SYFOVRE and EMPAVELI Sales in 2024, Eyes Expansion
Apellis Pharmaceuticals' 2024 10-K filing highlights strong revenue growth from SYFOVRE and EMPAVELI, while outlining strategic initiatives and ongoing clinical developments.
NASDAQ
APLS
Apellis Pharmaceuticals, INC
10-K/A: Apellis Pharmaceuticals Amends 10-K Filing to Correct Audit Matter Omissions
Apellis Pharmaceuticals files an amendment to its 10-K report to correct administrative errors related to audit reports and includes new certifications from its executives.
NASDAQ
APLS
Apellis Pharmaceuticals, INC
10-K: Apellis Pharmaceuticals Navigates SYFOVRE Challenges, Reports Strong Revenue Growth in 2023
Apellis Pharmaceuticals reports significant revenue growth driven by SYFOVRE and EMPAVELI, while addressing safety concerns and strategic pipeline adjustments in its 2023 10-K filing.